Brought to you by 
Pfizer marketing UCB's allergy antihistamine Zyrtec
13 Jul 1999
Executive Summary
Pfizer announced FDA approval of Zyrtec, a once-daily allergy pill it had licensed several years back from Belgian drug maker UCB Pharma. Pfizer took the product through US clinical testing and gets US and Canadian marketing rights.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer marketing UCB's allergy antihistamine Zyrtec
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice